Inanovate

Inanovate is a private, pre-revenue diagnostics company commercializing its proprietary Bio-ID platform, which integrates its foundational Longitudinal Assay Screening (LAS) technology. LAS is presented as a transformative method for protein analysis, analogous to real-time PCR for genomics, enabling highly multiplexed, quantitative serological testing without the need for serial dilutions. The company's mission is to enable access to the diagnostic power of the proteome for both clinical diagnostics and life sciences research, positioning its technology as a key enabler for next-generation diagnostics and therapeutics.

Longitudinal Assay Screening (LAS) - a kinetic, flow-based multiplex protein detection technology enabling quantitative measurement across a 7-log dynamic range without serial dilutions, integrated into the Bio-ID benchtop analyzer and cartridge system.

Inanovate competes in the multiplex immunoassay space against established platforms like Luminex's xMAP, Meso Scale Discovery's (MSD) electrochemiluminescence, and traditional ELISA. It differentiates by claiming a vastly superior dynamic range and kinetic data analysis. It also faces potential competition from high-plex proteomic technologies like Olink's proximity extension assay and SomaLogic's aptamer-based platforms.